Kraig Biocraft Laboratories Completes New Production Center, Expands Capacity more than Eightfold
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed a significant expansion of its spider silk production capacity. The company has constructed a new production center that increases its rearing capacity by more than eight times its current operations. This expansion is part of a strategic investment plan to rapidly scale production, following successful spring production trials.
The new facility features dedicated spaces for each BAM-1 parental line and a BAM-1 hybrid hatchery. It is expected to meet spider silk production needs through 2025. The company is now transitioning operations to this new space and finalizing backup power systems. The first production cycle in this facility, set to begin later this month, will be the largest single-cycle rearing of BAM-1 parental strains in the company's history.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completato un'importante espansione della sua capacità di produzione di seta di ragno. L'azienda ha costruito un nuovo centro di produzione che aumenta la sua capacità di allevamento di più di otto volte rispetto alle operazioni attuali. Questa espansione fa parte di un piano di investimento strategico per scalare rapidamente la produzione, a seguito di prove di produzione primaverile riuscite.
La nuova struttura comprende spazi dedicati per ciascuna linea parentale BAM-1 e un incubatoio ibrido BAM-1. Si prevede che soddisfi le esigenze di produzione di seta di ragno fino al 2025. L'azienda sta ora trasferendo le operazioni in questo nuovo spazio e finalizzando i sistemi di alimentazione di emergenza. Il primo ciclo di produzione in questa struttura, che inizierà più tardi questo mese, sarà il più grande allevamento in un singolo ciclo delle linee parentali BAM-1 nella storia dell'azienda.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completado una expansión significativa de su capacidad de producción de seda de araña. La empresa ha construido un nuevo centro de producción que aumenta su capacidad de crianza en más de ocho veces en comparación con las operaciones actuales. Esta expansión es parte de un plan estratégico de inversión para escalar rápidamente la producción, tras pruebas de producción exitosas en primavera.
La nueva instalación cuenta con espacios dedicados para cada línea parental BAM-1 y un criadero híbrido BAM-1. Se espera que satisfaga las necesidades de producción de seda de araña hasta 2025. La empresa ahora está transfiriendo las operaciones a este nuevo espacio y finalizando los sistemas de alimentación de respaldo. El primer ciclo de producción en esta instalación, que comenzará a finales de este mes, será el mayor ciclo de crianza única de las cepas parentales BAM-1 en la historia de la empresa.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미 실크 생산 능력을 대폭 확장했습니다. 이 회사는 기존 운영의 8배 이상에 해당하는 조련 능력을 증가시키는 새로운 생산 센터를 건설했습니다. 이번 확장은 성공적인 봄 생산 시험 후 빠르게 생산을 확대하기 위한 전략적 투자 계획의 일환입니다.
새 시설은 각 BAM-1 부모 라인과 BAM-1 하이브리드 부화장을 위한 전용 공간을 제공합니다. 2025년까지 거미 실크 생산 요구를 충족할 것으로 예상됩니다. 회사는 이제 이 새로운 공간으로 운영을 전환하고 있으며, 백업 전원 시스템을 최종 조정하고 있습니다. 이번 달 말 시작 예정인 이 시설의 첫 생산 사이클은 회사 역사상 BAM-1 부모 계통의 단일 사이클 조련 중 가장 클 것입니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a complété une expansion significative de sa capacité de production de soie d'araignée. L'entreprise a construit un nouveau centre de production qui augmente sa capacité d'élevage de plus de huit fois par rapport à ses opérations actuelles. Cette expansion fait partie d'un plan d'investissement stratégique pour accélérer la montée en puissance de la production, suite à des essais de production réussis au printemps.
La nouvelle installation comprend des espaces dédiés pour chaque ligne parentale BAM-1 et un couvoir hybride BAM-1. On s'attend à ce qu'elle réponde aux besoins de production de soie d'araignée jusqu'en 2025. L'entreprise est maintenant en train de transférer ses opérations vers ce nouvel espace et de finaliser les systèmes d'alimentation de secours. Le premier cycle de production dans cette installation, qui doit commencer plus tard ce mois-ci, sera le plus grand élevage en un seul cycle des souches parentales BAM-1 dans l'histoire de l'entreprise.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat eine bedeutende Expansion seiner Produktionskapazität für Spinnenseide abgeschlossen. Das Unternehmen hat ein neues Produktionszentrum gebaut, das seine Aufzuchtkapazität um mehr als das Achtfache der aktuellen Operationen erhöht. Diese Expansion ist Teil eines strategischen Investitionsplans zur schnellen Skalierung der Produktion, nach erfolgreichen Frühjahrsproduktionstests.
Die neue Einrichtung verfügt über spezielle Bereiche für jede BAM-1-Elterlinie und eine BAM-1-Hybridbrutstätte. Es wird erwartet, dass sie bis 2025 den Bedarf an Spinnenseide deckt. Das Unternehmen befindet sich jetzt im Übergang zu diesem neuen Raum und finalisiert die Backup-Stromsysteme. Der erste Produktionszyklus in dieser Einrichtung, der später in diesem Monat beginnen soll, wird die größte Einzel-Zyklen-Aufzucht von BAM-1-Elternstämmen in der Unternehmensgeschichte sein.
- Expansion of production capacity by more than 8 times
- New production center completed and ready for fall spider silk production
- Dedicated spaces for BAM-1 parental lines and hybrid hatchery
- Facility expected to meet production needs through 2025
- Largest single-cycle rearing of BAM-1 parental strains to begin this month
- None.
New Facility Online and Ready for Fall Spider Silk Production
ANN ARBOR, Mich., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed the second wave of its production expansion and is now transitioning spider silk manufacturing operations to its new, larger production center.
Following the overwhelming success of the spring production trials, Kraig Labs outlined a strategic investment plan to rapidly scale its production capacity, slated to take part in two waves. The first phase was completed in July, providing the necessary space for the Company to operate through the rainy season. The second and larger project was the construction of a new production center for the Company’s spider silk manufacturing operations.
Kraig Labs kicked off construction for this new production center in July. The new facility increases the Company’s rearing capacity by more than eight times its current operations. With dedicated production spaces for each BAM-1 parental line and a dedicated space for its BAM-1 hybrid hatchery, this new facility is expected to address the production space needed to meet the spider silk production schedule through 2025.
The Company is now transitioning its production operations and equipment to this new space, and finalizing the installation of backup power generation systems ahead of the next spider silk production cycle slated to begin at the end of this month.
Kicking off later this month, the first production cycle in this facility will be the largest single-cycle rearing of the BAM-1 parental strains in the Company's history. This rearing will, in turn, allow for the full utilization of this new and significantly expanded production space.
"As planned, this new facility is coming online just in time to support our fall production kick-off. The larger production center will allow us to fully leverage the supporting silk production infrastructure, maximizing the production output and bringing our spider silk manufacturing to the next level," said Company COO Jon Rice. "This center is the latest in a series of breakthroughs for Kraig Labs in commercial scale production of spider silk in 2024."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the new production capacity of Kraig Biocraft Laboratories (KBLB) after the expansion?
When will Kraig Biocraft Laboratories (KBLB) begin production in the new facility?
How long is the new production facility expected to meet Kraig Biocraft Laboratories' (KBLB) spider silk production needs?
What specific features does the new Kraig Biocraft Laboratories (KBLB) production center include?
